Engineered nano-immunopotentiators efficiently promote cancer immunotherapy for inhibiting and preventing lung metastasis of melanoma.

Engineered nano-immunopotentiators efficiently promote cancer immunotherapy for inhibiting and preventing lung metastasis of melanoma.

Publication date: Dec 01, 2019

Malignant melanoma, one of the most aggressive types of cancer easily metastasizes, making it extremely difficult to treat and unresponsive to current therapies. Recent breakthroughs in nanomaterials-based cancer immunotherapy have provided potential specific strategy for tumor and metastasis inhibition. With the development of nanotechnology, inorganic nanomaterials have been increasingly studied for their potential cancer therapeutic and molecular imaging functions. However, only iron-based nanomaterials have been approved by the Food and Drug Administration (FDA) in inorganic nanomedicines. For promising clinical application, a new type of nanocomposite is engineered by combining ultra-small iron oxide nanoparticles (FeO NPs) and ovalbumin (OVA), denoted as FeO-OVA nanocomposites in this study. Interestingly, this is the first time that FeO NPs are found as nano-immunopotentiators helping nanocomposites efficiently stimulate dendritic cell-based immunotherapy and potentially-activate macrophages. These nanocomposites efficiently stimulate the maturation level of bone marrow derived dendritic cell (BMDCs) and corresponding activation of T cells and also potentially-activate macrophages. With the help of the FeO nano-immunopotentiators (FeO NPs), this therapeutic and prophylactic FeO-OVA vaccine can not only efficiently inhibit the subcutaneous and metastatic B16-OVA tumor growth but also successfully prevent the formation of subcutaneous and metastatic tumor, providing a promising strategy for expanding the clinical use of Fe-based nanomaterials.

Luo, L., Iqbal, M.Z., Liu, C., Xing, J., Akakuru, O.U., Fang, Q., Li, Z., Dai, Y., Li, A., Guan, Y., and Wu, A. Engineered nano-immunopotentiators efficiently promote cancer immunotherapy for inhibiting and preventing lung metastasis of melanoma. 24966. 2019 Biomaterials (223):

Concepts Keywords
Bone Marrow Subcutaneous metastatic tumor
Dendritic Cell Immunotherapy
FDA Branches of biology
FeO Medicine
Immunotherapy Oncology
Inorganic Immunotherapy
Iron Virotherapy
Iron Oxide Nanomaterials
Lung Metastasis
Macrophages Macrophage
Malignant Melanoma Nanomedicine
Melanoma Melanoma
Metastasis Nanocomposite
Metastatic C-Met
Metastatic Tumor Biomaterials
Molecular Imaging
Nanocomposite
Nanocomposites
Nanomaterials
Nanoparticles
Nanotechnology
OVA
Prophylactic
Subcutaneous
Tumor
Vaccine

Semantics

Type Source Name
disease MESH cancer
disease MESH metastasis
disease MESH melanoma
pathway KEGG Melanoma
disease MESH development
drug DRUGBANK Iron

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *